# DEERFIELD MANAGEMENT COMPANY, L.P.

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1009258. Source: https://holderbook.com/funds/1009258-deerfield-management-company-l-p/

- Reported value: $9.6B
- Positions: 82
- Weight of the ten largest: 53.2%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| NUVALENT INC | [NUVL](https://holderbook.com/stocks/NUVL/) | $2.1B | 17,248,450 | 22.2% | 20 |
| BROOKDALE SR LIVING INC | - | $585.7M | 306,885,000 | 6.1% | 3 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $448.0M | 2,392,000 | 4.7% | 26 |
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $322.5M | 963,351 | 3.4% | 6 |
| VIATRIS INC | [VTRS](https://holderbook.com/stocks/VTRS/) | $320.9M | 20,206,170 | 3.3% | 23 |
| CENTENE CORP DEL | [CNC](https://holderbook.com/stocks/CNC/) | $314.6M | 4,901,000 | 3.3% | 31 |
| REVOLUTION MEDICINES INC | - | $251.7M | 200,000,000 | 2.6% | 1 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $247.6M | 457,000 | 2.6% | 6 |
| ARROWHEAD PHARMACEUTICALS IN | - | $240.5M | 200,000,000 | 2.5% | 2 |
| LEGEND BIOTECH CORP | [LEGN](https://holderbook.com/stocks/LEGN/) | $235.0M | 8,137,638 | 2.5% | 7 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $193.7M | 5,006,104 | 2.0% | 23 |
| GENMAB A/S | [GMAB](https://holderbook.com/stocks/GMAB/) | $188.6M | 6,865,000 | 2.0% | 2 |
| BROOKDALE SR LIVING INC | [BKD](https://holderbook.com/stocks/BKD/) | $187.2M | 11,637,032 | 2.0% | 31 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $168.1M | 3,916,400 | 1.8% | 6 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $157.0M | 1,979,669 | 1.6% | 4 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $151.8M | 1,451,014 | 1.6% | 4 |
| BIOCRYST PHARMACEUTICALS INC | [BCRX](https://holderbook.com/stocks/BCRX/) | $151.0M | 15,096,403 | 1.6% | 14 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMS](https://holderbook.com/stocks/NAMS/) | $144.5M | 4,264,789 | 1.5% | 10 |
| ACADIA HEALTHCARE COMPANY IN | [ACHC](https://holderbook.com/stocks/ACHC/) | $133.5M | 4,520,000 | 1.4% | 4 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $131.0M | 4,190,611 | 1.4% | 3 |
| ADAPTHEALTH CORP | [AHCO](https://holderbook.com/stocks/AHCO/) | $119.6M | 11,477,730 | 1.2% | 27 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $116.7M | 3,376,042 | 1.2% | 11 |
| CELCUITY INC | - | $113.8M | 100,000,000 | 1.2% | 1 |
| ARROWHEAD PHARMACEUTICALS IN | [ARWR](https://holderbook.com/stocks/ARWR/) | $113.2M | 1,389,055 | 1.2% | 4 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $109.7M | 1,125,313 | 1.1% | 2 |
| LARIMAR THERAPEUTICS INC | [LRMR](https://holderbook.com/stocks/LRMR/) | $108.6M | 35,606,974 | 1.1% | 25 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $106.8M | 3,958,000 | 1.1% | 1 |
| ALIGNMENT HEALTHCARE INC | - | $103.8M | 61,000,000 | 1.1% | 3 |
| IDEAYA BIOSCIENCES INC | [IDYA](https://holderbook.com/stocks/IDYA/) | $101.2M | 2,714,503 | 1.1% | 16 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $97.5M | 1,615,696 | 1.0% | 5 |
| IONIS PHARMACEUTICALS INC | - | $93.1M | 60,000,000 | 1.0% | 4 |
| SAVARA INC | [SVRA](https://holderbook.com/stocks/SVRA/) | $83.6M | 13,569,000 | 0.9% | 8 |
| LANTHEUS HLDGS INC | [LNTH](https://holderbook.com/stocks/LNTH/) | $83.5M | 752,999 | 0.9% | 3 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $82.6M | 3,779,900 | 0.9% | 2 |
| ZENAS BIOPHARMA INC | - | $80.3M | 67,200,000 | 0.8% | 2 |
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $76.3M | 1,332,836 | 0.8% | 2 |
| PFIZER INC | [PFE](https://holderbook.com/stocks/PFE/) | $73.2M | 3,040,000 | 0.8% | 2 |
| INDIVIOR PHARMACEUTICALS INC | [INDV](https://holderbook.com/stocks/INDV/) | $67.7M | 1,648,895 | 0.7% | 2 |
| BIO RAD LABS INC | [BIO](https://holderbook.com/stocks/BIO/) | $66.4M | 226,070 | 0.7% | 12 |
| ARS PHARMACEUTICALS INC | [SPRY](https://holderbook.com/stocks/SPRY/) | $60.1M | 7,503,812 | 0.6% | 15 |
| STOKE THERAPEUTICS INC | [STOK](https://holderbook.com/stocks/STOK/) | $59.7M | 1,823,500 | 0.6% | 3 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $58.3M | 1,086,000 | 0.6% | 14 |
| ENVISTA HOLDINGS CORPORATION | [NVST](https://holderbook.com/stocks/NVST/) | $58.2M | 2,210,100 | 0.6% | 8 |
| INSPIRE MED SYS INC | [INSP](https://holderbook.com/stocks/INSP/) | $57.9M | 1,296,862 | 0.6% | 5 |
| CAREDX INC | [CDNA](https://holderbook.com/stocks/CDNA/) | $56.9M | 1,997,618 | 0.6% | 4 |
| BOSTON SCIENTIFIC CORP | [BSX](https://holderbook.com/stocks/BSX/) | $56.1M | 1,315,000 | 0.6% | 1 |
| BELITE BIO INC | [BLTE](https://holderbook.com/stocks/BLTE/) | $55.0M | 357,199 | 0.6% | 3 |
| PARABILIS MEDICINES INC | [PBLS](https://holderbook.com/stocks/PBLS/) | $51.5M | 1,880,704 | 0.5% | 1 |
| CERTARA INC | [CERT](https://holderbook.com/stocks/CERT/) | $49.2M | 7,512,928 | 0.5% | 6 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $48.1M | 657,000 | 0.5% | 13 |
| LIVANOVA PLC | - | $46.5M | 34,280,000 | 0.5% | 5 |
| BRIDGEBIO ONCOLOGY THERAPEUT | [BBOT](https://holderbook.com/stocks/BBOT/) | $37.2M | 4,885,446 | 0.4% | 4 |
| TYRA BIOSCIENCES INC | [TYRA](https://holderbook.com/stocks/TYRA/) | $32.5M | 1,017,000 | 0.3% | 2 |
| MONOPAR THERAPEUTICS INC | [MNPR](https://holderbook.com/stocks/MNPR/) | $30.0M | 323,745 | 0.3% | 4 |
| SIONNA THERAPEUTICS INC | [SION](https://holderbook.com/stocks/SION/) | $30.0M | 680,916 | 0.3% | 6 |
| IMMUNOCORE HLDGS PLC | - | $27.1M | 30,000,000 | 0.3% | 6 |
| AVALYN PHARMACEUTICALS INC | [AVLN](https://holderbook.com/stocks/AVLN/) | $24.1M | 731,000 | 0.3% | 1 |
| FOGHORN THERAPEUTICS INC | [FHTX](https://holderbook.com/stocks/FHTX/) | $21.4M | 4,394,367 | 0.2% | 9 |
| BETA BIONICS INC | [BBNX](https://holderbook.com/stocks/BBNX/) | $20.7M | 1,324,000 | 0.2% | 6 |
| ALNYLAM PHARMACEUTICALS INC | [ALNY](https://holderbook.com/stocks/ALNY/) | $20.5M | 67,935 | 0.2% | 9 |
| BRIGHT MINDS BIOSCIENCES INC | [DRUG](https://holderbook.com/stocks/DRUG/) | $19.9M | 283,000 | 0.2% | 2 |
| ODYSSEY THERAPEUTICS INC | [ODTX](https://holderbook.com/stocks/ODTX/) | $19.6M | 1,046,139 | 0.2% | 1 |
| THE ONCOLOGY INSTITUTE INC | [TOI](https://holderbook.com/stocks/TOI/) | $18.2M | 3,360,052 | 0.2% | 19 |
| KYVERNA THERAPEUTICS INC | [KYTX](https://holderbook.com/stocks/KYTX/) | $17.8M | 2,000,000 | 0.2% | 3 |
| ALAMAR BIOSCIENCES INC | [ALMR](https://holderbook.com/stocks/ALMR/) | $16.3M | 600,000 | 0.2% | 1 |
| CHEMED CORP NEW | [CHE](https://holderbook.com/stocks/CHE/) | $14.0M | 30,000 | 0.1% | 1 |
| SPYGLASS PHARMA INC | [SGP](https://holderbook.com/stocks/SGP/) | $12.2M | 550,000 | 0.1% | 2 |
| NEOGENOMICS INC | - | $12.2M | 13,040,000 | 0.1% | 4 |
| ADAGENE INC | [ADAG](https://holderbook.com/stocks/ADAG/) | $11.2M | 2,666,666 | 0.1% | 1 |
| HEMAB THERAPEUTICS HLDGS INC | - | $10.1M | 275,000 | 0.1% | 1 |
| MOBIA MED INC | - | $9.0M | 670,752 | 0.1% | 1 |
| EMBECTA CORP | [EMBC](https://holderbook.com/stocks/EMBC/) | $8.3M | 2,534,961 | 0.1% | 11 |
| VERACYTE INC | [VCYT](https://holderbook.com/stocks/VCYT/) | $5.9M | 101,000 | 0.1% | 5 |
| ANNEXON INC | [ANNX](https://holderbook.com/stocks/ANNX/) | $3.3M | 583,913 | 0.0% | 24 |
| ALECTOR INC | [ALEC](https://holderbook.com/stocks/ALEC/) | $2.1M | 1,055,192 | 0.0% | 30 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMSW](https://holderbook.com/stocks/NAMSW/) | $2.0M | 92,787 | 0.0% | 15 |
| EDWARDS LIFESCIENCES CORP | [EW](https://holderbook.com/stocks/EW/) | $1.2M | 13,702 | 0.0% | 4 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $705.6K | 6,027 | 0.0% | 1 |
| HUMANA INC | [HUM](https://holderbook.com/stocks/HUM/) | $364.3K | 917 | 0.0% | 7 |
| THE ONCOLOGY INSTITUTE INC | [TOIIW](https://holderbook.com/stocks/TOIIW/) | $51.0K | 1,250,000 | 0.0% | 19 |
| PMV PHARMACEUTICALS INC | [PMVP](https://holderbook.com/stocks/PMVP/) | $11.8K | 8,790 | 0.0% | 5 |
| SURROZEN INC | [SRZNW](https://holderbook.com/stocks/SRZNW/) | $2.8K | 166,666 | 0.0% | 20 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +16.6% | +14.8% | +1.8% | 83% |
| Q1 2026 | +1.6% | -4.6% | +6.2% | 86% |
| Q4 2025 | +24.9% | +2.4% | +22.5% | 92% |
| Q3 2025 | +14.2% | +7.8% | +6.4% | 89% |
| Q2 2025 | +7.2% | +10.5% | -3.2% | 87% |
| Q1 2025 | -9.7% | -4.6% | -5.1% | 89% |
| Q4 2024 | -16.0% | +2.1% | -18.1% | 90% |
| Q3 2024 | +17.8% | +5.4% | +12.4% | 86% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $9.6B | 82 |
| Q1 2026 | $8.5B | 82 |
| Q4 2025 | $7.8B | 150 |
| Q3 2025 | $6.6B | 152 |
| Q2 2025 | $5.5B | 124 |
| Q1 2025 | $5.1B | 123 |
| Q4 2024 | $5.3B | 106 |
| Q3 2024 | $6.7B | 443 |
| Q2 2024 | $6.0B | 433 |
| Q1 2024 | $5.7B | 367 |
| Q4 2023 | $5.4B | 222 |
| Q3 2023 | $4.5B | 88 |